Tag: Europe
-
Chip Device Simulates Human Gut Interactions
11 May 2016. A device simulating the human intestine was shown in lab tests to generate similar responses to interactions between gut microbes and cells, as found in humans and animals. The HuMix system — short for Human Microbial Cross Talk — developed by researchers at University of Luxembourg and University of Arizona, is described…
-
Genomics, Data Tools Track MRSA Outbreaks in Europe
6 May 2016. A combination of whole-genome sequencing and data visualization tools now makes it possible to track the spread of antibiotic-resistant bacteria in European health facilities. A Europe-wide team led by Wellcome Trust Sanger Institute and Imperial College London described their software and service yesterday in the journal mBio. The authors call the spread…
-
Trial Underway Testing Antibody for Celiac Disease
5 May 2016. A clinical trial testing an engineered antibody therapy for celiac disease in people that do not respond to a gluten-free diet began treating its first patients. The trial is conducted by Celimmune LLC, a biopharmaceutical company in in Lebanon, New Jersey, but patients are recruited in Finland, where the rate of celiac…
-
Genomic Variations Reveal Cholesterol, Heart Disease Risks
4 May 2016. A review of genome and blood test records from a large group of people in Iceland identified genetic sequencing variations associated with risk factors connecting cholesterol levels to heart disease. Results of the analysis, conducted by deCode Genetics in Reykjavik, Iceland, appear this week in the journal Nature Genetics (paid subscription required).…
-
Drug Pricing Reform Even Big Pharma Might Like
2 May 2016. At a press event in Washington, D.C. last week, Representative Lloyd Doggett of Texas, a champion of lower prescription drug prices, took aim at drug companies and their business practices. “An unaffordable drug is 100 percent ineffective,” Doggett told an audience at Center for American Progress on 26 April. He noted that…
-
Challenge Seeks New Regenerative Tools with Stem Cells
29 April 2016. A challenge offered through InnoCentive is seeking new methods of harnessing adult stem cells for regenerative medicine. The competition has a total purse of $15,000 and a 24 June 2016 deadline for submissions. The sponsor of the challenge, pharmaceutical company Boehringer Ingelheim, also seeks research plans related to the challenge proposals, with…
-
Phones, Wearables Studied to Monitor Brain Disorders
27 April 2016. A project now underway in Europe plans to develop techniques for smartphones and wearable devices to monitor people with depression, epilepsy, and multiple sclerosis. The 5-year, €22 million ($US 25 million) initiative known as Remote assessment of disease and relapse – Central Nervous System, or Radar-CNS, is funded by the Innovative Medicines…
-
NeuroVive, Penn Partner on Traumatic Brain Injury
26 April 2016. A pharmaceutical company in Sweden is collaborating with University of Pennsylvania’s medical school in preclinical studies of a new drug that protects against long term damage caused by traumatic brain injury. Financial terms of the agreement between NeuroVive Pharmaceutical AB in Lund, Sweden and the university were not disclosed. NeuroVive develops drugs…
-
Genetic Techniques Quickly Build Crop Disease Resistance
26 April 2016. Plant scientists in the U.K. developed genetic engineering techniques that quickly clone resistance to plant diseases affecting wheat, soybeans, and potatoes. The techniques are described in articles appearing in the 25 April issue of the journal Nature Biotechnology (paid subscription required). Teams from the John Innes Centre and Sainsbury Laboratory in Norwich…
-
Flair4IT Helps Cloud Computing Become Mainstream in the EU
– Sponsored Content – 11 April 2016. Flair4IT, a UK based IT agency, has been working on making the cloud more mainstream in the EU. They have looked specifically at software applications and infrastructures. To enable the market to become more aware of cloud computing, and to make it as common as what it is…